Therapeutic Strategies for Systemic Necrotizing Vasculitides
Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities prolong survival and reduce the number of relapses, while decreasing the severity and...
Gespeichert in:
| Veröffentlicht in: | Allergology International 2007, Vol.56 (2), p.105-111 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111 |
|---|---|
| container_issue | 2 |
| container_start_page | 105 |
| container_title | Allergology International |
| container_volume | 56 |
| creator | Guillevin, Loïc Pagnoux, Christian |
| description | Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities prolong survival and reduce the number of relapses, while decreasing the severity and number of side effects. Many prospective clinical trials were organized by the French Vasculitis Study Group and the European Vasculitis Study group, and have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies include immunomodulating methods, like plasma exchanges, or products, like intravenous immunoglobulins, or, more recently, new agents called biotherapies. Some of them have achieved promising positive effects, for example, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials. |
| doi_str_mv | 10.2332/allergolint.R-07-144 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20306547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1323893015308546</els_id><sourcerecordid>20306547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6074-8cd635d6478e2dab415a7ef086a50e6432ed8b3b96004c4c1325c1166251bd663</originalsourceid><addsrcrecordid>eNp9kFtr3DAQhUVoyP0fhLJPfXM6uttQCiU0aSEkkNurkOXZrYLX3kpyS_LrM8kuJE_Rw4yQznycOYwdczgRUoqvvu8xLcY-DuXkugJbcaW22B5VqLhuxCe6SyGrupGwy_ZzfgDgwjZ2h-1yqwyQcI99u_2Dya9wKjHMbkryBRcR82w-ptnNYy64pPdLDGks8SkOi9m9z2HqY4kd5kO2Pfd9xqNNP2B3Zz9vT39VF1fnv09_XFTBgFVVHTojdWeUrVF0vlVce4tzqI3XgEZJgV3dyrYxACqoQLZ14NwYoXnbGSMP2Jc1d5XGvxPm4pYxB-x7P-A4ZSdAgtHKklCtheQ354Rzt0px6dOj4-BeUnPvUnPXDqyjvGjs84Y_tUvs3oY2MZHgfC2g3xh8Pw4EQPcwTmmgxV34r_wrUgAhAbQBQU054KCp0FGNqZuXVb6vSUh5_YuYXA4Rh0DchKG4bowfe30G8sSYHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20306547</pqid></control><display><type>article</type><title>Therapeutic Strategies for Systemic Necrotizing Vasculitides</title><source>J-STAGE Free</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Open Access Titles of Japan</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Guillevin, Loïc ; Pagnoux, Christian</creator><creatorcontrib>Guillevin, Loïc ; Pagnoux, Christian ; Assistance Publique-Hopitaux de Paris ; Universite Paris-Rene-Descartes ; Department of Internal Medicine ; Hopital Cochin</creatorcontrib><description>Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities prolong survival and reduce the number of relapses, while decreasing the severity and number of side effects. Many prospective clinical trials were organized by the French Vasculitis Study Group and the European Vasculitis Study group, and have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies include immunomodulating methods, like plasma exchanges, or products, like intravenous immunoglobulins, or, more recently, new agents called biotherapies. Some of them have achieved promising positive effects, for example, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials.</description><identifier>ISSN: 1323-8930</identifier><identifier>EISSN: 1440-1592</identifier><identifier>DOI: 10.2332/allergolint.R-07-144</identifier><identifier>PMID: 17460440</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; ANCA ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antigens, CD20 - immunology ; Antiviral Agents - therapeutic use ; Blood Vessels - pathology ; Churg-Strauss Syndrome - immunology ; Churg-Strauss Syndrome - therapy ; Cyclophosphamide - therapeutic use ; Etanercept ; Granulomatosis with Polyangiitis - immunology ; Granulomatosis with Polyangiitis - therapy ; Hepatitis B - complications ; Hepatitis C - complications ; HIV Infections - complications ; Humans ; Immunoglobulin G - therapeutic use ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Factors - therapeutic use ; immunosuppressants ; Immunosuppressive Agents - therapeutic use ; Infliximab ; Necrosis ; Plasma Exchange ; polyarteritis nodosa ; Polyarteritis Nodosa - immunology ; Polyarteritis Nodosa - therapy ; Receptors, Tumor Necrosis Factor - therapeutic use ; Rituximab ; Treatment Outcome ; Tumor Necrosis Factor-alpha - immunology ; vasculitis ; Vasculitis - drug therapy ; Vasculitis - immunology ; Vasculitis - pathology ; Vasculitis - therapy ; Vasculitis - virology ; Wegener's granulomatosis</subject><ispartof>Allergology International, 2007, Vol.56 (2), p.105-111</ispartof><rights>2007 Japanese Society of Allergology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6074-8cd635d6478e2dab415a7ef086a50e6432ed8b3b96004c4c1325c1166251bd663</citedby><cites>FETCH-LOGICAL-c6074-8cd635d6478e2dab415a7ef086a50e6432ed8b3b96004c4c1325c1166251bd663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17460440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guillevin, Loïc</creatorcontrib><creatorcontrib>Pagnoux, Christian</creatorcontrib><creatorcontrib>Assistance Publique-Hopitaux de Paris</creatorcontrib><creatorcontrib>Universite Paris-Rene-Descartes</creatorcontrib><creatorcontrib>Department of Internal Medicine</creatorcontrib><creatorcontrib>Hopital Cochin</creatorcontrib><title>Therapeutic Strategies for Systemic Necrotizing Vasculitides</title><title>Allergology International</title><addtitle>Allergol Int</addtitle><description>Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities prolong survival and reduce the number of relapses, while decreasing the severity and number of side effects. Many prospective clinical trials were organized by the French Vasculitis Study Group and the European Vasculitis Study group, and have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies include immunomodulating methods, like plasma exchanges, or products, like intravenous immunoglobulins, or, more recently, new agents called biotherapies. Some of them have achieved promising positive effects, for example, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>ANCA</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antigens, CD20 - immunology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Blood Vessels - pathology</subject><subject>Churg-Strauss Syndrome - immunology</subject><subject>Churg-Strauss Syndrome - therapy</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Etanercept</subject><subject>Granulomatosis with Polyangiitis - immunology</subject><subject>Granulomatosis with Polyangiitis - therapy</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis C - complications</subject><subject>HIV Infections - complications</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Factors - therapeutic use</subject><subject>immunosuppressants</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infliximab</subject><subject>Necrosis</subject><subject>Plasma Exchange</subject><subject>polyarteritis nodosa</subject><subject>Polyarteritis Nodosa - immunology</subject><subject>Polyarteritis Nodosa - therapy</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><subject>vasculitis</subject><subject>Vasculitis - drug therapy</subject><subject>Vasculitis - immunology</subject><subject>Vasculitis - pathology</subject><subject>Vasculitis - therapy</subject><subject>Vasculitis - virology</subject><subject>Wegener's granulomatosis</subject><issn>1323-8930</issn><issn>1440-1592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFtr3DAQhUVoyP0fhLJPfXM6uttQCiU0aSEkkNurkOXZrYLX3kpyS_LrM8kuJE_Rw4yQznycOYwdczgRUoqvvu8xLcY-DuXkugJbcaW22B5VqLhuxCe6SyGrupGwy_ZzfgDgwjZ2h-1yqwyQcI99u_2Dya9wKjHMbkryBRcR82w-ptnNYy64pPdLDGks8SkOi9m9z2HqY4kd5kO2Pfd9xqNNP2B3Zz9vT39VF1fnv09_XFTBgFVVHTojdWeUrVF0vlVce4tzqI3XgEZJgV3dyrYxACqoQLZ14NwYoXnbGSMP2Jc1d5XGvxPm4pYxB-x7P-A4ZSdAgtHKklCtheQ354Rzt0px6dOj4-BeUnPvUnPXDqyjvGjs84Y_tUvs3oY2MZHgfC2g3xh8Pw4EQPcwTmmgxV34r_wrUgAhAbQBQU054KCp0FGNqZuXVb6vSUh5_YuYXA4Rh0DchKG4bowfe30G8sSYHg</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Guillevin, Loïc</creator><creator>Pagnoux, Christian</creator><general>Elsevier B.V</general><general>JAPANESE SOCIETY OF ALLERGOLOGY</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>2007</creationdate><title>Therapeutic Strategies for Systemic Necrotizing Vasculitides</title><author>Guillevin, Loïc ; Pagnoux, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6074-8cd635d6478e2dab415a7ef086a50e6432ed8b3b96004c4c1325c1166251bd663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>ANCA</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antigens, CD20 - immunology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Blood Vessels - pathology</topic><topic>Churg-Strauss Syndrome - immunology</topic><topic>Churg-Strauss Syndrome - therapy</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Etanercept</topic><topic>Granulomatosis with Polyangiitis - immunology</topic><topic>Granulomatosis with Polyangiitis - therapy</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis C - complications</topic><topic>HIV Infections - complications</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Factors - therapeutic use</topic><topic>immunosuppressants</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infliximab</topic><topic>Necrosis</topic><topic>Plasma Exchange</topic><topic>polyarteritis nodosa</topic><topic>Polyarteritis Nodosa - immunology</topic><topic>Polyarteritis Nodosa - therapy</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><topic>vasculitis</topic><topic>Vasculitis - drug therapy</topic><topic>Vasculitis - immunology</topic><topic>Vasculitis - pathology</topic><topic>Vasculitis - therapy</topic><topic>Vasculitis - virology</topic><topic>Wegener's granulomatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guillevin, Loïc</creatorcontrib><creatorcontrib>Pagnoux, Christian</creatorcontrib><creatorcontrib>Assistance Publique-Hopitaux de Paris</creatorcontrib><creatorcontrib>Universite Paris-Rene-Descartes</creatorcontrib><creatorcontrib>Department of Internal Medicine</creatorcontrib><creatorcontrib>Hopital Cochin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Allergology International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guillevin, Loïc</au><au>Pagnoux, Christian</au><aucorp>Assistance Publique-Hopitaux de Paris</aucorp><aucorp>Universite Paris-Rene-Descartes</aucorp><aucorp>Department of Internal Medicine</aucorp><aucorp>Hopital Cochin</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Strategies for Systemic Necrotizing Vasculitides</atitle><jtitle>Allergology International</jtitle><addtitle>Allergol Int</addtitle><date>2007</date><risdate>2007</risdate><volume>56</volume><issue>2</issue><spage>105</spage><epage>111</epage><pages>105-111</pages><issn>1323-8930</issn><eissn>1440-1592</eissn><abstract>Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities prolong survival and reduce the number of relapses, while decreasing the severity and number of side effects. Many prospective clinical trials were organized by the French Vasculitis Study Group and the European Vasculitis Study group, and have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies include immunomodulating methods, like plasma exchanges, or products, like intravenous immunoglobulins, or, more recently, new agents called biotherapies. Some of them have achieved promising positive effects, for example, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>17460440</pmid><doi>10.2332/allergolint.R-07-144</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1323-8930 |
| ispartof | Allergology International, 2007, Vol.56 (2), p.105-111 |
| issn | 1323-8930 1440-1592 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20306547 |
| source | J-STAGE Free; MEDLINE; DOAJ Directory of Open Access Journals; Open Access Titles of Japan; EZB-FREE-00999 freely available EZB journals |
| subjects | Adrenal Cortex Hormones - therapeutic use ANCA Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - immunology Antiviral Agents - therapeutic use Blood Vessels - pathology Churg-Strauss Syndrome - immunology Churg-Strauss Syndrome - therapy Cyclophosphamide - therapeutic use Etanercept Granulomatosis with Polyangiitis - immunology Granulomatosis with Polyangiitis - therapy Hepatitis B - complications Hepatitis C - complications HIV Infections - complications Humans Immunoglobulin G - therapeutic use Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use immunosuppressants Immunosuppressive Agents - therapeutic use Infliximab Necrosis Plasma Exchange polyarteritis nodosa Polyarteritis Nodosa - immunology Polyarteritis Nodosa - therapy Receptors, Tumor Necrosis Factor - therapeutic use Rituximab Treatment Outcome Tumor Necrosis Factor-alpha - immunology vasculitis Vasculitis - drug therapy Vasculitis - immunology Vasculitis - pathology Vasculitis - therapy Vasculitis - virology Wegener's granulomatosis |
| title | Therapeutic Strategies for Systemic Necrotizing Vasculitides |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T14%3A00%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Strategies%20for%20Systemic%20Necrotizing%20Vasculitides&rft.jtitle=Allergology%20International&rft.au=Guillevin,%20Lo%C3%AFc&rft.aucorp=Assistance%20Publique-Hopitaux%20de%20Paris&rft.date=2007&rft.volume=56&rft.issue=2&rft.spage=105&rft.epage=111&rft.pages=105-111&rft.issn=1323-8930&rft.eissn=1440-1592&rft_id=info:doi/10.2332/allergolint.R-07-144&rft_dat=%3Cproquest_cross%3E20306547%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20306547&rft_id=info:pmid/17460440&rft_els_id=S1323893015308546&rfr_iscdi=true |